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LncRNA AK054921 and AK128652 Are
Potential Serum Biomarkers and
Predictors of Patient Survival With
Alcoholic Cirrhosis
Zhihong Yang,1–3 Ruth A Ross,4 Shi Zhao,5 Wanzhu Tu,5 Suthat Liangpunsakul,4,6,7 and Li Wang1–3,8,9
Alcoholic liver disease (ALD) is one of the leading causes of chronic liver disease. Recent studies have demonstrated the
roles of long noncoding RNAs (lncRNAs) in the pathogenesis of several disease processes. However, the roles of lncRNAs
in patients with ALD remain unexplored. Global proﬁling for human lncRNAs from peripheral blood RNA was per-
formed in a well-characterized cohort of healthy controls (HC; n5 4), excessive drinkers (ED) without liver disease
(n5 4), and those with alcoholic cirrhosis (AC) with different severities (n5 12). The expression of unique lncRNA signa-
tures were validated in a separate cohort of HC (n5 17), ED (n5 19), AC (n5 48), and human liver tissues with ALD
(n5 19). A detailed analysis of plasma lncRNAs in AC subjects with different severities compared with HC identiﬁed 244
commonly up-regulated lncRNAs and 181 commonly down-regulated lncRNAs. We further validated top 20 most differ-
entially up- and down-regulated lncRNAs in ED and AC compared with HC and also determined the expression of
selected lncRNAs in human liver tissues with or without AC. Among those lncRNAs, AK128652 and AK054921 were
two of the most abundantly expressed lncRNAs in normal human plasma and liver, and their levels were signiﬁcantly ele-
vated in AC. The prognostic signiﬁcance of AK128652 and AK054921 was determined in 48 subjects with AC who were
followed prospectively for 520 days. The expression of AK128652 and AK054921 was inversely associated with survival in
patients with AC. Conclusion: lncRNAs AK054921 and AK128652 are potential biomarkers to predict the progression to
ALD in individuals with excessive alcohol consumption and are predictors of survival in patients with AC. (Hepatology
Communications 2017;1:513–523)
Alcoholic liver disease (ALD), a major compli-cation of excessive alcohol use, is one of theleading causes of chronic liver disease, with
substantial morbidity and mortality.(1) ALD consists
of a spectrum of pathological changes ranging from
alcoholic steatosis to ﬁbrosis and cirrhosis.(2) Alcohol-
induced steatosis occurs in most if not all patients who
consume alcohol excessively, but can be reversed with
abstinence.(3) However, continued drinking can lead to
alcoholic cirrhosis in up to 15%-20% of excessive
drinkers in their lifetime,(4) suggesting that other
factors in addition to alcohol drinking per se are likely
involved in the pathogenesis as well as the disease
progression.
The genetic components for susceptibility to ALD
have been studied, including genes involving in alcohol
metabolism,(5) innate immune responses,(6) oxidative
stress,(7) and lipid homeostasis.(8) A variant in the
patatin-like phospholipase domain-containing protein
3 (PNPLA3) gene (rs738409) has been found(9) and
conﬁrmed(10) to be associated with increased risk of
ALD. Subjects with this variant were also at high risk
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for progression from clinically silent to clinically appar-
ent ALD.(11) Metabolomics also discovered major
metabolites altered by alcohol in mouse models.(12)
Despite these discoveries, a large variability remains
unexplained, suggesting that other nongenetic factors
might be involved.
The new landscape of human transcriptome along
with the identiﬁcation of noncoding RNAs (ncRNAs)
has uncovered their importance in the pathophysiology
of human diseases.(13) Long noncoding RNAs
(lncRNAs) are a subgroup of ncRNAs with approxi-
mately 200 nucleotides(14) and are often expressed at
lower levels when compared with protein-coding
genes.(15) lncRNA H19 was found to be highly
induced during liver injury and was involved in chole-
static liver ﬁbrosis.(16) Metabolic derangements in fat
cell metabolism and adipogenesis, commonly seen in
excessive alcohol use subjects, are also under the regu-
lation of lncRNAs.(17) The lncRNA steroid receptor
RNA activator promoted hepatic steatosis by repres-
sing adipose triglyceride lipase.(18) Nonetheless, studies
on the roles of lncRNAs in human ALD remain
unexplored.(13)
In this study, we hypothesized that speciﬁc
lncRNAs are critical for the progression from excessive
drinkers without underlying liver disease to ALD and
that their unique role underpins the clinical observa-
tion on why only a subset of excessive drinkers develop
ALD. To test this hypothesis, global proﬁling for
human lncRNAs from peripheral blood RNA was per-
formed in a well characterized cohort of healthy con-
trols (HC), excessive drinkers (ED) without liver
diseases, and those with alcohol-induced cirrhosis
(AC). We next determined the association of the
unique sets of lncRNAs that were identiﬁed from
peripheral blood with those in the livers from patients
with ALD. Furthermore, we determined the prognos-
tic signiﬁcance of this unique lncRNA signature on
the survival outcomes in patients with alcoholic
cirrhosis.
Subjects and Methods
HUMAN SUBJECT COHORT
Healthy controls (HC), excessive drinkers without
underlying liver disease (ED), and those with alcoholic
cirrhosis (AC) were enrolled. Healthy controls were
recruited from outpatient clinic at the Roudebush Vet-
erans Administration Medical Center (VAMC), Indi-
anapolis, Indiana. Excessive drinkers were recruited
from Fairbanks Drug and Alcohol Treatment Center
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(Indianapolis, IN). They were at least 21 years old
without underlying medical illnesses such as chronic
obstructive pulmonary disease, congestive heart failure,
diabetes, cancer, or chronic renal failure. These sub-
jects had normal results for aspartate aminotransferase,
alanine aminotransferase, total bilirubin, albumin,
platelet count, and international normalized ratio
(INR). Subjects with a history of jaundice or signs of
end-stage liver disease (e.g., ascites, hepatic encepha-
lopathy, or variceal bleeding), history of chronic hepa-
titis B or C infection, history of any systemic infection
within 4 weeks before the study were excluded.
Subjects with known diagnosis of AC who attended
the liver clinic at the Roudebush VAMC or at Indiana
University were recruited between October 2012 and
March 2015. These patients had history of alcohol
consumption averaging at least 80 g per day (for men)
or 50 g per day (for women) for at least 10 years.(19)
This criterion is based on epidemiological evidence of
the relationship between alcohol consumption and cir-
rhosis.(20) The diagnosis of cirrhosis was made using
radiographic imaging compatible with cirrhosis and/or
history of ascites, grade 2 or higher hepatic encepha-
lopathy and/or the presence of esophageal varices on
upper gastrointestinal endoscopy, or biopsy-proven cir-
rhosis, with exclusion of hepatitis B or C, autoimmune
liver disease, hemochromatosis, and Wilson disease.
Patients were followed prospectively until death, liver
transplantation, or study closure date of July 31, 2016.
The study was approved by the Institutional Review
Board at the Indiana University Purdue University
Indianapolis, Fairbanks Alcohol Rehabilitation Center,
and Roudebush VAMC Research and Development
Program. Written informed consent was obtained
from each participant.
DATA AND BIOSAMPLE
COLLECTION
At enrollment, baseline demographic data, clinical
characteristics, and laboratory tests were obtained.
Baseline Child-Pugh and Model for End-Stage Liver
Disease (MELD) scores were calculated for subjects
with AC. Subjects were then stratiﬁed into those with
compensated (Child-Pugh class A, AC1) and those
with decompensated liver diseases (Child-Pugh class B
or C and AC2 or AC3, respectively). Peripheral blood
was collected from venipuncture into the PAXgene
Blood RNA tube (Qiagen, catalog #762165). The
blood sample was gently inverted and stored at 280oC
within 2 hours of collection.
HUMAN LIVER TISSUES
The human liver specimens from normal controls
(n5 24) and subjects with AC (n5 19) were obtained
through the Liver Tissue Cell Distribution System
(Minneapolis, MN) funded by National Institutes of
Health Contract # HSN276201200017C, as described
previously.(15,16,21,22) The study was reviewed and
approved by the University of Connecticut Institu-
tional Review Board.
GLOBAL PROFILING OF HUMAN
lncRNAs
Peripheral blood RNAs were extracted using a
QIAamp RNA Blood Mini Kit (Qiagen, Hilden, Ger-
many) according to the manufacturer’s guidelines.
Blood RNAs from HC (n5 4), ED without liver dis-
ease (n5 4), and AC (AC1 from Child-Pugh class A,
n5 4; AC2 from Child-Pugh class B, n5 4; and AC3
from Child-Pugh class C, n5 4) were subjected to
global transcriptomic proﬁling using the Arraystar
human lncRNA microarray version 3.0 (Arraystar,
Rockville, MD). Quantitative polymerase chain reac-
tion (qPCR) was used to validate the expression of the
top 20 peripheral blood lncRNAs in a separate cohort
of 17 HC, 19 ED, and 48 AC subjects as well as in
the liver tissues from controls (n5 24) and subjects
with AC (n5 19).
STATISTICAL ANALYSIS
Basic descriptive statistics, including mean, standard
deviations (SD), and frequencies (percentages) were
used. All the experiments were performed in triplicate
and repeated at least two times. The data are presented
as the mean6 standard error of the mean (SEM). Sta-
tistical analysis was performed using a Student t test
for unpaired data to compare the values between the
two groups and one-way analysis of variance among
multiple groups. P< 0.05 was considered statistically
signiﬁcant.
Survival analyses were performed to determine the
prognostic signiﬁcance of the selected lncRNAs and
the outcomes in subjects with AC (n5 48). We exam-
ined the distributions of all variables, and those with
skewed distributions were logarithmically transformed.
We examined the time to mortality using a survival
analysis. Individuals who did not die during the study
follow-up were considered censored at the end of the
observation window. Kaplan-Meier curves were used
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to estimate the distributions of the survival time in dif-
ferent groups. Cox regression models were used to
assess the effects of independent variables. Univariate
analyses were ﬁrst conducted to explore the association
between individual predictors and the survival out-
come. Log-rank tests were used for categorical predic-
tors and Wald tests were used for continuous
predictors. All the main effects and two-way interac-
tions were included in the initial proportional hazard
model. The ﬁnal model was achieved by eliminating
the variables with signiﬁcance level exceeding 0.05 in a
stepwise fashion. Risk scores for individual patients
were calculated by using the patient characteristics and
parameter estimates from ﬁnal model. Harrell’s C sta-
tistic/generalized receiver operating curve area was
used to examine the prognostic accuracy of these
markers in the predication model, in comparison with
the MELD score.
We validated the proposed scoring method using a
bootstrap procedure by randomly selecting 80% of sub-
jects and repeating the model 1000 times. Finally, we
used logistic regression models to predict the probabil-
ity of death within 3, 6, and 12 months using the
newly derived score. Areas under the receiver operating
curve (AUROCs) were reported to quantify the capaci-
ties of discrimination of the new score and the MELD
score. For these analyses, deaths within 3, 6, and 12
months were recorded as events. All the statistical
analyses were conducted using R version 3.2.4.
P< 0.05 was used as the signiﬁcance level.
Results
TRANSCRIPTOMICS
IDENTIFICATION OF
DIFFERENTIALLY EXPRESSED
PERIPHERAL BLOOD lncRNAs IN
HC, ED, AND AC WITH
DIFFERENT SEVERITIES
The Arraystar Human LncRNA Microarray version
3.0 was used for the global proﬁling of human
lncRNAs (30,600 lncRNAs). For the exploration
phase, 20 human peripheral blood RNA samples from
ﬁve groups (HC, ED, AC1, AC2, AC3, n5 4/group)
were analyzed. This high throughput analysis identi-
ﬁed signiﬁcantly differentially expressed lncRNAs.
Importantly, unique lncRNA signature changes
occurred from HC to ED (Fig. 1A). In addition, more
differentially expressed lncRNAs were observed in
AC3 versus HC or ED compared with AC2 or AC1
versus HC or ED (Fig. 1A). We also observed that the
numbers of differentially expressed peripheral blood
lncRNAs were signiﬁcantly increased in AC3 versus
AC1 compared with AC2 versus AC1 (Fig. 1B), sug-
gesting that they were more pronounced once the dis-
ease severity worsened.
Detailed analysis of these lncRNAs in different
Child-Pugh classes compared with HC identiﬁed 244
commonly up-regulated lncRNAs (Fig. 1C) and 181
commonly down-regulated lncRNAs (Fig. 1D) in
AC1, AC2, and AC3. In addition, the number of
uniquely up-regulated lncRNAs were increased from
252 (in AC1) to 1417 (in AC3, Fig. 1C), whereas the
number of uniquely down-regulated lncRNAs
increased from 100 (in AC1) to 1594 (in AC3, Fig.
1D).
We aimed to discover speciﬁc sets of lncRNA signa-
tures across the spectrum of the three cohorts and,
more importantly, during the progression from ED to
AC. The differential expression of these lncRNAs in
AC patients with different severities based on Child-
Pugh classiﬁcation (AC1, AC2, and AC3) was
expected to be distinctive. Based on the microarray
data, the 20 most differentially up-regulated (Support-
ing Fig. 1) and down-regulated (Supporting Fig. 2)
lncRNAs were observed in ED, AC1, AC2, and AC3
compared with HC. The identiﬁcation of these
uniquely regulated lncRNAs that are distinct in AC
patients may have the potential to serve as noninvasive
diagnostic markers for a subset of subjects with exces-
sive alcohol use who develop ALD or cirrhosis.
VALIDATION OF PERIPHERAL
BLOOD lncRNAs EXPRESSION
Although microarray is a powerful tool allowing the
examination of the expression of thousands of
lncRNAs simultaneously, one technical limitation is
that false microarray data can be generated from
degraded mRNA. In addition, interindividual varia-
tions in gene expression must not be ignored.
To validate the expression of lncRNAs, we selected
potential targets with a false discovery rate< 0.05, raw
intensity higher than 500, and fold change> 2 or< 2
(FC> 2 or< 2) in each group. Using these criteria, we
identiﬁed 19 lncRNAs, which are provided in Sup-
porting Table 1. The validation was performed in a
separate cohort of 17 HC, 19 ED, and 48 AC (Sup-
porting Table 2) using qPCR. Among the 19
lncRNAs we analyzed, only a few showed expression
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patterns similar to the microarray data. The ED up-
regulated RP11-178F10.2 (Fig. 2A) and AC1 up-
regulated FTX (Fig. 2B) were most highly expressed in
AC2, whereas ANP32A-IT1 showed no signiﬁcance in
all groups (data not shown). The AC3 up-regulated
RP11-549B18.2 and XLOC_003832 were both highly
elevated in AC2 (Fig. 2C). Among AC3 down-
regulated lncRNAs, LOC100233156 showed a constant
and progressive down-regulation from ED to AC, with
the lowest expression in AC3 (Fig. 2D). In contrast,
AK128652 was highly elevated in AC2, whereas
AC093642.3 showed no changes in all groups (Fig. 2D).
Among commonly up-regulated lncRNAs, AC004854.4
and XLOC_010595 were induced in AC2, whereas
CTC-297N7.5 showed a tendency of induction in AC3
(Fig. 2E). It was noted that the expression pattern of the
validated lncRNAs in each group differed from the
microarray data. This was likely attributed to the hetero-
geneity of the samples used for microarray analysis (four
samples per group) and those used for qPCR analysis.
Nonetheless, several lncRNAs were identiﬁed to be
highly elevated in AC2. The list of primers used for
qPCR analysis is provided in Supporting Table 3.
To expand the validation to more lncRNAs, we
selected the ones with FC> 2 or< 2 and adjusted
P< .05. RP11-605F22.2 and XLOC_010517 were
both markedly down-regulated in ED and AC (Fig.
3A). BX247990 was similarly induced in both AC1
and AC2, whereas AK054921 levels were similarly
increased in AC2 and AC3 (Fig. 3B). RP11-367J11.3,
XLOC_007914, and XLOC_004372 showed a pro-
gressive induction in AC2 versus AC1 (Fig. 3C).
Interestingly, AC005324.6 expression was reduced in
ED and AC3 but remained unchanged in AC1 and
AC2 when compared with HC (Fig. 3D).
IDENTIFYING SIMILARLY
ACTIVATED lncRNAs IN
PERIPHERAL BLOOD AND LIVER
Thus far, all the lncRNAs were validated indepen-
dently using individual qPCR. To have a better under-
standing and comparison about the relative abundance
of each lncRNA, we selected nine lncRNAs (under-
lined in bold in Figs. 2 and 3) and examined their basal
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FIG. 1. Volcano plot displaying differentially expressed plasma lncRNAs in three study cohorts of human AC. (A,B) The log2 ratio
(x axis) and 2log10 adjusted P values (y axis) were plotted in the form of volcano plots for excessive drinkers (ED) versus healthy
controls (HC), alcoholic cirrhosis (AC) versus HC, and AC versus ED comparisons. Red color represents signiﬁcantly up-regulated
(right) and down-regulated (left) lncRNAs, respectively (FC< 2 or> 2 and adjusted P< 0.05). Gray color represents the signiﬁcant
with small fold change (above the green line) (FC< 1.5 or> 1.5) and the nonsigniﬁcant change (below the green line). Total RNAs
from 20 human blood samples (n5 4 per group) were analyzed by Arraystar Human LncRNA Microarray version 3.0. AC15Child-
Pugh class A, AC25Child-Pugh class B, AC35Child-Pugh class C. (C,D) Venn diagrams showing total numbers and overlapping
up-regulated (C) and down-regulated (D) lncRNAs between AC1, AC2, and AC3.
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FIG. 3. Validation of plasma lncRNAs expression changes in AC patients based on FC and P value gating. (A-D) qPCR of plasma lncRNAs
RP11-605F22.2 and XLOC_010517 (A); BX247990 and AK054921 (B); RP11-367J11.3, XLOC_007914, and XLOC_004372 (C); and
AC005324.6 (D) from HC, ED, AC1, AC2, and AC3. Total RNAs were isolated from 10 new human plasma samples from each group. Data
are expressed as the mean6 standard error of the mean (triplicate assays). *P< 0.05, **P< 0.01, ***P< 0.005 versus HC.
                                                                                                                                      
                                                                                                                                      
FIG. 2. Validation of plasma lncRNA expression changes in AC patients based on false discovery rate and raw intensity gating. (A-
D) qPCR of plasma lncRNAs RP11-178F10.2 (A); FTX (B); RP11-549B18.2 and XLOC_003832 (C); LOC100233156,
AK128652, and AC093642.3 (D); and AC004854.4, XLOC_010595, and CTC-297N7.5 (E) from HC, ED, AC1, AC2, and AC3.
Total RNAs were isolated from 10 new human plasma samples from each group. Data are expressed as the mean6 standard error of
the mean (triplicate assays). *P< 0.05, **P< 0.01, ***P< 0.005, ****P< 0.001 versus HC.
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levels simultaneously in 17 HC samples.
XLOC_007914 was the most highly expressed
lncRNA in human peripheral blood, followed by
AK128652, AK054921, and BX247990 (Fig. 4A).
The liver is one of the major organs that is affected by
alcohol-induced tissue injury. To determine whether the
differentially expressed lncRNAs from the peripheral blood
also occur in the liver tissues, we examined the levels of the
same sets of lncRNAs in 24 normal human liver speci-
mens. XLOC_007914 again showed the highest expres-
sion in human livers, followed by AK054921, RP11-
178F10.2, and AK128652 (Fig. 4B). The results suggest
that the identiﬁed peripheral blood lncRNAs could repre-
sent the lncRNAs that are secreted from the liver.
To further conﬁrm the expression of those nine
lncRNAs (Fig. 4A), we determined their levels in the
blood samples of 19 ED and 48 AC with different
severity using qPCR, and the results were presented as
fold change versus HC for a better comparison. lncRNAs
BX247990 and RP11-367J11.3 (blue underline) exhib-
ited a different expression pattern (Fig. 4C) compared
with the prior analyses (Fig. 3B,C), likely reﬂecting indi-
vidual sample variations. Seven lncRNAs (green under-
line) showed similar expression changes compared with
previous results (Figs. 2 and 3). Among them,
AK128652 displayed the highest induction in AC2, fol-
lowed by XLOC_003832, RP11-178F10.2, and RP11-
549B18.2. Unlike other lncRNAs for which levels were
highly elevated in AC2 but declined in AC3, AK054921
remained at an approximately 2-fold increase in AC3.
To establish the potential correlation with human liver
diseases, we examined the expression of the nine
lncRNAs in human liver specimens, including normal
control (n5 24) and AC (n5 19). AK128652 exhibited
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FIG. 4. Identifying commonly elevated lncRNAs in plasma and liver of human liver diseases. (A,B) Basal expression of lncRNAs in human
plasma from normal controls (n5 17) (A) and in human liver from normal controls (n5 24) (B). Data are expressed as the mean6 standard
error of the mean (triplicate assays). (C) qPCR of plasma lncRNAs fromHC (n5 17), ED (n5 19), AC1 (n5 18), AC2 (n5 16), and AC3
(n5 14). Data are expressed as FC with HC set as 1. *P< 0.05, **P< 0.01, ***P< 0.005, ****P< 0.001 versus HC. (D) qPCR of hepatic
lncRNAs from human liver specimens for normal controls (n5 24) and individuals with AC (n5 19). Data are expressed as FC with normal
controls set as 1. *P< 0.05, **P< 0.01, *** P< 0.005 versus HC. *P< 0.05, **P< 0.01, *** P< 0.005, **** P< 0.001 versus normal.
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the highest induction in AC (approximately 5-fold) fol-
lowed by AK054921 approximately 2-fold) (Fig. 4D).
PROGNOSTIC SIGNIFICANCE OF
lncRNAs AND SURVIVAL IN
PATIENTS WITH ALCOHOLIC
CIRRHOSIS
Our goal was to identify lncRNAs that were
expressed at relatively high levels in human peripheral
blood as well as in the liver of patients with AC. From
the results shown in Fig. 4C and 4D, both AK128652
and AK054921 (red underline) met our selection crite-
ria for further analysis. The expression of AK128652
and AK054921 levels in each sample of subjects with
HC, ED, AC1, AC2, and AC3 was shown in Figure 5.
As expected, the level of AK128652 was highest in the
samples of AC2 patients and the levels of AK054921
showed progressive increased in the samples of AC
patients with different severity (Fig. 5A).
We next determined the prognostic signiﬁcance of
these two lncRNAs in the cohort of 48 subjects with AC.
During the median follow-up of 520 days, 34% of patients
died. The median survival was 3.4 years. The overall sur-
vival for subjects with different disease severity is shown in
Figure 5B. The survival rates at 3 months, 6 months, and
1 year were 77%, 75%, and 69%, respectively. We found
that logarithmic transformed AK054921 and AK128652,
i.e., logeAK054921 and logeAK128652, were signiﬁcantly
associated with the survival time through interaction terms
(Supporting Table 4).
Using the estimated regression coefﬁcients in the
linear predictors of the proportional hazard model,
we calculated a risk score based on the variables that
were in MELD, in addition to the expression
levels of AK054921 and AK128652: 3.53 logeINR
115.03 logebilirubin 28.13 logecreatinine 11.33
logeAK054921 1 3.63 logeAK128652 1 2.93 loge
XLOC_00383212.13 logebilirubin3 logeAK054921
2 2.43 loge bilirubin3 logeAK128652 22.63 loge
bilirubin3 logeXLOC_00383211.33 logecreatinine3
logeXLOC_00383213.33 logecreatinine3 logeAK
128652 This score corresponded to the chance of sur-
vival of an individual patient given his or her values of
the predictive markers. The Harrell’s C statistic for
this selected model was 93.6%, which was higher than
that of MELD (C statistic of 82.4%).
Using a bootstrap procedure for validation, we found
that that the average value of the C-statistic of the new
predictive score was 93.6% with a standard deviation
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FIG. 5. AK128652 and AK054921 expression association with patient survival. (A) qPCR of plasma lncRNAs AK128652 and
AK054921 expression in new cohorts of individual samples from HC, ED, AC1, AC2, and AC3. Each dot represents an individual
sample. Total RNAs were isolated from human plasma. Data are expressed as the mean6 standard error of the mean (triplicate assays)
and as FC with average of HC set as 1. *P< 0.05, **P< 0.01, ***P< 0.005, ****P< 0.001 versus HC. (B) Survival curve of AC sub-
jects with different severity. (C-E) Harrell’s C statistic in predicting survival at 3, 6, and 12 months in patients with AC using the
risk score calculation including AK128652 and AK054921 expression.
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of 1.9%. Using this model, we found that AUROC in
predicting mortality at 3, 6, and 12 months was 95.3%,
96.1%, and 96.7%, respectively (Fig. 5C-E). Our
results indicate that both AK054921 and AK128652
not only represent the unique lncRNAs, which may
play roles in the pathogenesis of ALD, but also have
the prognostic signiﬁcance on the survival.
Discussion
LncRNAs have been shown to regulate gene func-
tion at a transcriptional and posttranscriptional
level.(23) They also play a role in epigenetic regulation
of the DNA.(24) Over the past few years, signiﬁcant
advancements have been made in identifying the criti-
cal roles of lncRNAs in the disease pro-
cesses.(13,14,17,25-28) Furthermore, levels of lncRNA
expression have been investigated as disease bio-
markers, either for diagnostic or prognostic purposes.
For instance, the levels of differentiation antagonizing
nonprotein coding RNA may be useful in diagnosis of
hepatocellular carcinoma.(29) The lncRNA metastasis-
associated lung adenocarcinoma transcript 1 was found
to be a good predictor for hepatocellular carcinoma
recurrence after liver transplantation.(30) lncRNA 16
(ENST00000539303) and Sox2 overlapping transcript
have been associated with prognosis in patients with
lung and gastric cancers, respectively.(31,32)
Excessive alcohol consumption has an effect on sev-
eral organ systems. In the liver, excessive alcohol use
can lead to a broad spectrum of liver disorders, ranging
from simple steatosis to severe forms of liver injury,
including steatohepatitis, ﬁbrosis/cirrhosis, and hepa-
tocellular carcinoma.(2) The underlying mechanisms of
alcohol-induced liver injury are complex, involving the
derangement in hepatic lipid metabolism, innate
immune responses, and epigenetic regulation(33-35); all
of these processes are also under control by
lncRNAs.(17,24,26) Interestingly, only a subset of sub-
jects with excessive alcohol use develops ALD. Given
that lncRNAs have been involved in several pathways
associated with the pathogenesis of ALD, we hypothe-
sized that excessive alcohol drinking results in the
alterations of hepatic lncRNAs. These distinct
lncRNAs are secreted into the circulation and can be
detected in the peripheral blood upon hepatocyte
injury. lncRNAs that are unique to ED or individuals
with AC, or common to ED and AC but with a pro-
gressive change in expression with disease severity
could be used as the biomarkers to predict disease pro-
gression and clinical outcomes. To the best of our
knowledge, our study is the ﬁrst to comprehensively
analyze and establish lncRNA signatures in the periph-
eral blood to differentiate HC, ED without liver dis-
ease, and individuals with AC. The common lncRNA
signatures that were identiﬁed in the peripheral blood
were also conﬁrmed in the liver tissues from subjects
with AC.
Our results showed the lncRNA signature that is
unique in ED versus HC but not in AC. This ED sig-
nature is likely served as a signature that differentiates
ED from HC and AC and may not be involved in the
progression from ED to AC. When we compared the
lncRNA signatures between ED and AC groups, we
found substantial numbers of lncRNAs that are com-
mon in ED and AC but absent in HC. We postulated
that these lncRNA signatures are likely regulated by
alcohol and may contribute to ALD progression. The
schematic diagram demonstrating the overall results of
our study is shown in Figure 6. Using the selection cri-
teria as deﬁned above and after the validation both
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FIG. 6. Schematic showing the major ﬁndings of the study.
Speciﬁc hepatic lncRNAs are altered (up- or down-regulated) by
chronic alcohol consumption. They are secreted (through mecha-
nisms as yet undeﬁned) into the circulation. The levels of
lncRNAs in blood are associated with liver disease stages, and
their changes represent the liver lncRNA signatures altered by
alcohol-induced liver injury. These lncRNAs may serve as serum
biomarkers and can be used to predict ALD progression. Red:
up-regulated; green: down-regulated; red underline: associated
with patient survival; green underline: most signiﬁcantly down-
regulated.
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from peripheral blood as well as liver tissues, we found
that lncRNAs AK128652 and AK054921 are associ-
ated with the progression from ED to AC. Not only
were the levels of expression of these 2 lncRNAs paral-
lel with the severity of AC, they were also inversely
associated with long-term survival in these patients. It
is important to note that the function of these two
lncRNAs are not known; as such, further in vitro and
in vivo experiments should be undertaken to explore
the molecular mechanism of these two lncRNAs in the
pathogenesis of ALD.
In conclusion, our exploratory study demonstrated
that lncRNAs AK054921 and AK128652 are potential
biomarkers to predict the progression to ALD in indi-
viduals with excessive alcohol consumption and are
predictors of survival with patients with AC.
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